Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome.

AIMS Cardiomyopathy produces significant mortality in patients with Friedreich ataxia (FA), a genetic disorder that produces intra-mitochondrial iron accumulation. We sought to test the hypothesis that abnormal myocardial perfusion reserve and fibrosis represent early manifestations of cardiomyopathy. METHODS AND RESULTS Twenty-six patients with genetically proven FA ages 36 ± 12 years without cardiomyopathy and eight controls underwent cardiac magnetic resonance with adenosine. Precontrast imaging for myocardial iron estimation was performed. Myocardial perfusion reserve index (MPRI) was quantified using the normalized upslope of myocardial enhancement during vasodilator stress vs. rest. Left ventricular (LV) mass and volumes were computed from short-axis cine images. Serologies included lipids, and platelets were isolated for iron quantification using inductively coupled plasma mass spectrometry. Left ventricular ejection fraction and mass averaged 64.1 ± 8.3% and 62.7 ± 16.7 g/m², respectively, indicating preserved systolic function and absence of significant hypertrophy. Myocardial perfusion reserve index quantification revealed significantly lower endocardial-to-epicardial perfusion reserve in patients vs. controls (0.80 ± 0.18 vs. 1.22 ± 0.36, P = 0.01). Lower MPRI was predicted by increased number of metabolic syndrome (met-S) features (P < 0.01). Worse concentric remodelling occurred with increased GAA repeat length (r = 0.64, P < 0.001). Peripheral platelet iron measurement showed no distinction between patients and controls (5.4 ± 8.5 × 10⁻⁷ vs. 5.5 ± 2.9 × 10⁻⁷ ng/platelet, P = 0.88), nor did myocardial T2* measures. CONCLUSIONS Patients with FA have abnormal myocardial perfusion reserve that parallels met-S severity. Impaired perfusion reserve and fibrosis occur in the absence of significant hypertrophy and prior to clinical heart failure, providing potential therapeutic targets for stage B cardiomyopathy in FA and related myocardial diseases.

[1]  D. Lanska.  Adams and Victor’s Principles of Neurology , 2010 .

[2]  P. Galan,et al.  Macrovascular and microvascular dysfunction in the metabolic syndrome , 2010, Hypertension Research.

[3]  F. Collins.  Opportunities for Research and NIH , 2010, Science.

[4]  May H. Han.  Adams and Victor's Principles of Neurology, 9th Edition , 2009 .

[5]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[6]  D. Geschwind,et al.  Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARγ pathway as a therapeutic target in Friedreich’s ataxia , 2009, Human molecular genetics.

[7]  A. Filla,et al.  Low-dose idebenone treatment in Friedreich’s ataxia with and without cardiac hypertrophy , 2009, Journal of Neurology.

[8]  S. Raman,et al.  Myocardial ischemia in asymptomatic adults with repaired aortic coarctation. , 2009, International journal of cardiology.

[9]  D. Levy,et al.  Relations of Biomarkers Representing Distinct Biological Pathways to Left Ventricular Geometry , 2008, Circulation.

[10]  P. Bauer,et al.  Cardiomyopathy in Friedreich's ataxia‐assessment by cardiac MRI , 2007, Movement disorders : official journal of the Movement Disorder Society.

[11]  K. Fischbeck,et al.  Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. , 2007, Archives of neurology.

[12]  S. Rivaud-Pechoux,et al.  Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. , 2007, Archives of neurology.

[13]  M. Carraway,et al.  Metabolic capacity regulates iron homeostasis in endothelial cells. , 2006, Free radical biology & medicine.

[14]  E. Nagel.  Faculty Opinions recommendation of Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging. , 2006 .

[15]  M. Hallett,et al.  Measuring Friedreich ataxia: Interrater reliability of a neurologic rating scale , 2005, Neurology.

[16]  Robert G Weiss,et al.  Is the failing heart energy starved? On using chemical energy to support cardiac function. , 2004, Circulation research.

[17]  M. Koenig,et al.  Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia. , 2004, Human molecular genetics.

[18]  A. Nicolosi,et al.  Mitochondrial Sources of H2O2 Generation Play a Key Role in Flow-Mediated Dilation in Human Coronary Resistance Arteries , 2003, Circulation research.

[19]  R. Kim,et al.  How we perform delayed enhancement imaging. , 2003, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[20]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[21]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Circulation.

[22]  L. Schöls,et al.  Idebenone in patients with Friedreich ataxia , 2001, Neuroscience Letters.

[23]  P. Nihoyannopoulos,et al.  Echocardiographic Characterization of Cardiomyopathy in Friedreich’s Ataxia With Tissue Doppler Echocardiographically Derived Myocardial Velocity Gradients , 2000, Circulation.

[24]  J. Cooper,et al.  Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia. , 2000, Human molecular genetics.

[25]  M. Thun,et al.  Body-mass index and mortality in a prospective cohort of U.S. adults. , 1999, The New England journal of medicine.

[26]  N. Jakubowski,et al.  Sector field mass spectrometers in ICP-MS , 1998 .

[27]  J. Mendell,et al.  Identification of a missense mutation in a Friedreich's ataxia patient: implications for diagnosis and carrier studies. , 1998, American journal of medical genetics.

[28]  R. Williamson,et al.  The correlation of clinical phenotype in Friedreich ataxia with the site of point mutations in the FRDA gene , 1998, Neurogenetics.

[29]  M. Pandolfo,et al.  Frataxin Shows Developmentally Regulated Tissue-Specific Expression in the Mouse Embryo , 1997, Neurobiology of Disease.

[30]  A Dürr,et al.  Clinical and genetic abnormalities in patients with Friedreich's ataxia. , 1996, The New England journal of medicine.

[31]  P. Patel,et al.  Friedreich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion , 1996, Science.

[32]  J S Child,et al.  Cardiac involvement in Friedreich's ataxia: a clinical study of 75 patients. , 1986, Journal of the American College of Cardiology.

[33]  D. Stumpf,et al.  Friedreich ataxia , 1979, Neurology.

[34]  D. Pennell,et al.  Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. , 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[35]  S. Raman,et al.  Myocardial ischemia and right ventricular dysfunction in adult patients with sickle cell disease. , 2006, Haematologica.